"Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called \"HER dimerization inhibitors\". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth."@en . . . "K16AIQ8CTM" . "XC13" . "380610-27-5" . "L01" .